Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Slide on Nasdaq Delisting Warning

NEW YORK, Sept. 20 (GenomeWeb News) - Shares of Sequenom's stock are down 4.88 percent, or $.04, at $.78 today following news this morning that the company has received a delisting warning letter from the Nasdaq exchange.

 

Sequenom received the letter from Nasdaq's listing qualifications department because the company's shares do not comply with Nasdaq's $1 minimum bid price requirement.

 

Sequenom now has 180 days, or until March 15, 2006, to regain compliance by closing at or above $1 per share for at least 10 consecutive business days. If the company does not regain compliance by this deadline, its common stock could be delisted from the exchange.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.